Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Trial of Petrelintide in Healthy and Overweight/Obese Subjects
NCT05613387Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of petrelintide in obesity and Overweight (4 arms), sponsored by Zealand Pharma. Primary endpoint: Incidence of treatment emergent adverse events at Day 176. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05613387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613387.